4SC AG: 4SC announces further EMA feedback relating to Resminostat's (Kinselby) Marketing Authorisation Application

Planegg-Martinsried (pta035/28.04.2025/16:10 UTC+2)

Planegg-Martinsried, Germany, 28 April 2025 – The Management Board of 4SC AG ("4SC") (Frankfurt Stock Exchange, Prime Standard: VSC; ISIN: DE000A3E5C40) was informed by the European Medicines Agency (EMA) today that based on its review of the final data and the Company's response to the Day-180 Assessment Report, 4SC has been invited to an Oral Explanation before the Committee for Medicinal Products for Human Use (CHMP) at its end of May meeting. Following that meeting the CHMP is expected to then take a decision as to whether or not to issue a positive opinion regarding the Company's Market Authorization Application (MAA) for Resminostat (Kinselby) in the EU.

—————————————————————————
Information and Explanation of the Issuer to this News:

Forward-looking information

Information set forth in this press release contains forward-looking statements, which involve risks and uncertainties. The forward-looking statements contained herein represent the judgement of 4SC as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond 4SC's control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. 4SC expressly disclaims any obligation or undertaking to release any updates or revisions to any such statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

For further information, please contact:

4SC AG

ir-pr@4sc.com

Optimum Strategic Communications

Nick Bastin, Vareen Outhonesack

Phone: +44 20 3922 0891

4SC@optimumcomms.com

(end)

Emitter:	4SC AG Fraunhoferstr. 22 82152 Planegg-Martinsried Germany
Contact Person:	Jason Loveridge
Phone:	+49 89 700763-0
E-Mail:	ir-pr@4sc.com
Website:	www.4sc.de
ISIN(s):	DE000A3E5C40 (Share)
Stock Exchange(s):	Regulated Market in Frankfurt; Free Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate